Gallium Ga 68 FAPi-46

Phase 2Radiopharmaceutical

JJonsson Comprehensive Cancer Center

Gallium Ga 68 FAPi-46 is one of 35 small molecule programs targeting Metastatic Sarcoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic SarcomaActive, not recruiting

Pancreatic CarcinomaRecruiting

ProspectiveActive, not recruiting

Metastatic SarcomaPhase 1

Active, not recruiting

Pancreatic CarcinomaPhase 2

Recruiting

ProspectivePhase 1

Active, not recruiting

Competition

Competitive Landscape

31 competitors in Prospective

#DrugCompanyPhaseTrials

Tnkase

Roche

Approved

1 2

Zeposia

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

1 3

Nexavar

Bayer

Phase 3

2 4

Venclexta

AbbVie

Phase 3

2 5

Cytosar

Teva

Phase 3

1 6

Xiidra

BBausch Health Americas, Inc.

Approved

1 7

Mulpleta

IItalian Network for Tumor Biotherapy Foundation

Approved

1 8

Beyfortus

BeiGene

Phase 2

1 9

Imbruvica

PPharmacyclics LLC.

Phase 2

1 10

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Active, not recruiting

Prospective

NCT04459273

Q4 2027

Phase 1Active, not recruiting

Metastatic Sarcoma

NCT04457258

Q2 2028

Phase 2Recruiting

Pancreatic Carcinoma

NCT05518903

Clinical

Trials by Indication[1]

Prospective1 trial

Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers

Active, not recruiting·JJonsson Comprehensive Cancer Center·Phase 1·NCT04459273·26 enrolled

Metastatic Sarcoma1 trial

PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Sarcoma: An Exploratory Biodistribution Study With Histopathology Validation

Active, not recruiting·JJonsson Comprehensive Cancer Center·Phase 1·NCT04457258·18 enrolled

Pancreatic Carcinoma1 trial

Quantitative In Vivo 68Ga-Fibroblast-Activation-Protein-Inhibitors (FAPI)-46 PET Imaging of Cancer-Associated Fibroblasts (CAFs) in Pancreatic Ductal Adenocarcinoma (PDA)

Recruiting·MMayo Clinic·Phase 2·NCT05518903·130 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Gallium Ga 68 FAPi-46. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gallium Ga 68 FAPi-46 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gallium Ga 68 FAPi-46. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jonsson Comprehensive Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Radiopharmaceutical[2]
Highest Phase: Phase 2[1]
Company: JJonsson Comprehensive Cancer Center

Gallium Ga 68 FAPi-46

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Q2 2028

Trials by Indication[1]

Prospective1 trial

Metastatic Sarcoma1 trial

Pancreatic Carcinoma1 trial

References

Drug Info

Quick Facts

Related News